Patents

  1. US 2018-62623861A1 Pipecolic esters for inhibition of the proteasome, Jan. 30, 2019
  2. US2018/035869S mall molecule Proteasome Activators and uses thereof, Dec. 13, 2018
  3. US 2018/0282280A1 Quinoline-based proteasome inhibitors and uses thereof, Oct. 4, 2018.
  4. US 62/539,049. Treatment of malignancies. July 31, 2018
  5. US 62/515,403. Enhancement of proteasome activity for the treatment of neurodegenerative diseases. June 5, 2018
  6. US Provisional patent 62/479,805. Quinoline-based proteasome inhibitors. March 31, 2017
  7. US 8,552,206 B2. and European Patent: 03731545.4. NF-kB inhibitors and uses thereof. Oct. 8, 2013
  8. US 8,252,942 B2. Substituted imidazoline compounds. Aug. 12, 2012
  9. US 7,193,079 B1. Preparation of hymendialdisine derivates and use thereof. March 20, 2007
  10. US 6,878,735 B2. Multi-substituted imidazolines and method of use thereof. April 12, 2005